Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.42 |
| ▸ | GCGR | P47871 | 6/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | GIPR | P48546 | 1/20 | 0.39 |
| ▸ | GCG | P01275 | 2/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065318 | 0.86 | CSF1R (0.52) | CSF1RHDAC6 | |
| SCHEMBL12056808 | 0.86 | HDAC6 (0.45) | CSF1RCCNCCDK8CDK2HDAC6 | |
| SCHEMBL12056811 | 0.86 | CCNT1 (0.41) | CSF1RCCNCCDK8CDK2HDAC6 | |
| SCHEMBL906189 | 0.85 | CSF1R (0.43) | CSF1RCCNCCDK8CDK2HDAC6 | |
| SCHEMBL4814302 | 0.84 | CDK2 (0.36) | CSF1RCCNCCDK8CDK2HDAC6 | |
| SCHEMBL12056804 | 0.84 | FYN (0.41) | CSF1RCCNCCDK8CDK2HDAC6 | |
| SCHEMBL12056813 | 0.82 | CCNT1 (0.42) | CSF1RUTS2RPDE2ACCNCCDK8 | |
| SCHEMBL12056800 | 0.81 | CSF1R (0.36) | CSF1RCCNCCDK8CDK2HDAC6 | |
| SCHEMBL906176 | 0.78 | CSF1R (0.46) | CSF1RCCNCCDK8CDK2CYP19A1 | |
| SCHEMBL28763820 | 0.78 | CSF1R (0.46) | CSF1RCCNCCDK8CDK2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140221396-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130274263-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD | 2013-10-17 | — | — | US | disclosed |
| US-8394806-B2 | 2-phenyl pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-03-12 | — | — | US | disclosed |
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-20110269760-A1 | TUBULIN INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-11-03 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | TUBB1, TUBA1C, TUBB | CSF1R 2097/4885GCGR 2831/4885GLP1R 2188/4885 |
| US-20160031835-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885GCGR 4160/4885GLP1R 4504/4885 |
| US-20080194583-A1 | Tubulin Inhibitors | TUBB1, TUBB3, TUBA1C | CSF1R 2475/4885GCGR 4222/4885GLP1R 4546/4885 |
| US-20110269760-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885GCGR 4160/4885GLP1R 4504/4885 |
| US-20130274263-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885GCGR 4160/4885GLP1R 4504/4885 |
| US-20140221396-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CSF1R 2477/4885GCGR 4160/4885GLP1R 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.